Administration of Intranasal Midazolam for Anxiety in Palliative Care

NCT06330584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Anxiety
Acute Anxiety
Palliative Care

Interventions

DRUG: Placebo Nasal Spray 0 mg/spray
DRUG: Midazolam Nasal Spray 0.45 mg/spray
DRUG: Midazolam Nasal Spray 0.9 mg/spray

Sponsor

Insel Gruppe AG, University Hospital Bern